Corporate news
Ibn Sina Pharma [ISPH] – FY2025 Results: Strong Growth in Revenue and Net Profit
The company reported revenue of EGP 76.6 billion by the end of FY2025, compared to EGP 55.8 billion in FY2024, reflecting a YoY growth of 37%.
Gross profit increased by 47% YoY, reaching EGP 6 billion compared to EGP 4 billion in the comparable period.
Interest burden recorded a slight decline, standing at 71% compared to 75% during the same period last year.
The company achieved a 55% YoY increase in net profit, amounting to EGP 952 million compared to EGP 615 million in FY2024.
Walaa Mosalam – Prime Research
WMosalam@egy.primegroup.org